Seminars in Oncology
Volume 34 , Pages S1-S15 , April 2007

The Management of Recurrent Ovarian Cancer

  • Ronald M. Bukowski

      Affiliations

    • The Cleveland Clinic Foundation Taussig Cancer Center and the Cleveland Clinic Foundation Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
    • Dr Bukowski has received research grant support from Bristol-Myers Squibb and Eli Lilly and Company. Dr Ozols has served as a consultant to Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Novartis Pharmaceuticals, Telik, Inc, and Unither Pharmaceuticals, and has served on an advisory committee and as a speaker for Eli Lilly and Company. Dr Markman has served as a consultant to Celgene, Eli Lilly and Company, Genentech, GlaxoSmithKline, Merck & Co, Inc, Telik, Inc, and Tibotec Therapeutics.
    • Corresponding Author InformationAddress correspondence to Ronald M. Bukowski, MD, Experimental Therapeutics Program, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195
    • ,
  • Robert F. Ozols

      Affiliations

    • Fox Chase Cancer Center, Philadelphia, PA.
    • Dr Bukowski has received research grant support from Bristol-Myers Squibb and Eli Lilly and Company. Dr Ozols has served as a consultant to Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Novartis Pharmaceuticals, Telik, Inc, and Unither Pharmaceuticals, and has served on an advisory committee and as a speaker for Eli Lilly and Company. Dr Markman has served as a consultant to Celgene, Eli Lilly and Company, Genentech, GlaxoSmithKline, Merck & Co, Inc, Telik, Inc, and Tibotec Therapeutics.
    • ,
  • Maurie Markman

      Affiliations

    • The University of Texas M. D. Cancer Center, Houston, TX.
    • Dr Bukowski has received research grant support from Bristol-Myers Squibb and Eli Lilly and Company. Dr Ozols has served as a consultant to Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Novartis Pharmaceuticals, Telik, Inc, and Unither Pharmaceuticals, and has served on an advisory committee and as a speaker for Eli Lilly and Company. Dr Markman has served as a consultant to Celgene, Eli Lilly and Company, Genentech, GlaxoSmithKline, Merck & Co, Inc, Telik, Inc, and Tibotec Therapeutics.

References 

  1. American Cancer Society: Cancer Facts and Figures 2007. Available at: http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf (accessed April 4, 2007)
  2. Ozols RF, Schwartz PE, Eifel PJ. Treatment of advanced-stage ovarian cancer. In:  DeVita VT,  Hellman S,  Rosenberg SA, et al. editor. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott-Raven; 1997;p. 1514–1539
  3. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–1329
  4. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–3200
  5. Mant JW, Vessey MP. Mortality trends in ovarian cancer. In:  Lawton FG,  Nejit JP,  Swenerton KD editor. Epithelial Cancer of the Ovary. London: BMJ Publishing; 1995;p. 1–12
  6. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In:  DeVita VT,  Hellman S,  Rosenberg SA, et al. editor. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott-Raven; 1997;p. 1502–1534
  7. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. In: Atlas of Tumor Pathology, 3rd Series; Fascicle 23. Washington, DC: Armed Forces Institute of Pathology; 1998;
  8. Lee KR, Tavassoli FA, Prat J. Surface epithelial stromal tumors. In:  Tavassoli FA,  Devilee P editor. Pathology and Genetics: Tumors of the Breast and Genital Organs. Lyon, France: IARC Press; 2003;p. 117–145
  9. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005;18(suppl 2):S19–S32
  10. Cvetkovic D. Early events in ovarian oncogenesis. Reprod Biol Endocrinol. 2003;1:68
  11. Cook J. Family history of ovarian cancer. Curr Obstet Gynaecol. 2002;12:47–51
  12. Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998;16:2417–2425
  13. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283:2260–2265
  14. Purdie DM, Bain CJ, Siskind V, et al. Ovulation and risk of epithelial ovarian cancer. Int J Cancer. 2003;104:228–232
  15. Riman T, Dickman PW, Nilsson S, et al. Risk factors for invasive epithelial ovarian cancer: Results from a Swedish case-control study. Am J Epidemiol. 2002;156:363–373
  16. Lacey JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA. 2002;288:334–341
  17. Duarte-Franco E, Franco EL. Other gynecologic cancers: Endometrial, ovarian, vulvar and vaginal cancers. BMC Womens Health. 2005;4(suppl 1):S14
  18. Benedet JL, Bender H, Jones H, et al. FIGO Committee on Gynecologic Oncology FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet. 2000;70:209–262
  19. De Pree N, Wils J Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg. Chemotherapy consisting of cisplatin, doxorubicin and cyclophosphamide as an adjunct to surgery in stage Ic-II epithelial ovarian carcinoma. Anticancer Res. 1989;9:1873–1875
  20. Bolis G, Colombo N, Pecorelli S, et al. G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). Ann Oncol. 1995;6:887–893
  21. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer (Results of two prospective randomized trials). N Engl J Med. 1990;322:1021–1027
  22. International Collaborative Ovarian Neoplasm Trial 1. A randomized trial of adjuvant chemotherapy in women with early stage ovarian cancer. J Natl Cancer Inst. 2003;95:125–132
  23. Trimbos JB, Vergote I, Bolis G, et al. Impact of Adjuvant chemotherapy and surgical staging in early stage carcinoma: European Organisation for Research and Treatment of Cancer – Adjuvant ChemoTherapy in Ovarian Neoplasm trail. J Natl Cancer Inst. 2003;95:113–125
  24. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm 1; European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy in Ovarian Neoplasm trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95:105–112
  25. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;102:432–439
  26. National Cancer Institute: Carboplatin plus paclitaxel with or without continued low-dose paclitaxel in treating patients with early-stage ovarian cancer. Available at: http://www.cancer.gov/clinicaltrials/view_clinicaltrials.aspx?version=patient&cdrid=66732&clickitem=ClinicalTrialsSearchResult (accessed November 8, 2006)
  27. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6
  28. Ozols RF. Systemic therapy for ovarian cancer: Current status and new treatments. Semin Oncol. 2006;33(suppl 6):S3–S11
  29. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21:2460–2465
  30. Gadducci A, Cosio S, Conte PF, et al. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol. 2005;55:153–166
  31. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43
  32. Ozols RF, Bookman MA, Young RC. Intraperitoneal chemotherapy for ovarian cancer. N Engl J Med. 2006;354:1641–1643
  33. Copeland LJ, Bookman M, Trimble E. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol Oncol. 2003;90:S1–S7
  34. Burger RA, Sill M, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2005;22:457s;(abstr 5009)
  35. Garcia AA, Oza AM, Hirte G, et al. Interitm report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium trial. J Clin Oncol. 2005;22:455;(abstr 5000)
  36. National Cancer Institute: carboplatin and paclitaxel with or without bevacizumab in treating patients with stage III or stage IV ovarian epithelial or primary peritoneal cancer. Available at: http://www.clinicaltrials.gov/ct/gui/show/NCT00262847?order=11 (accessed November 8, 2006)
  37. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389–393
  38. Gore ME, Fryatt I, Wiltshaw E, et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990;36:207–211
  39. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–2106
  40. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699–4707
  41. Gonzalez-Martin AJ, Calvo E, Bover I, et al. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: A GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol. 2005;16:749–755
  42. Bolis G, Scarfone G, Giardina G, et al. Associazione per la Ricerca in Ginecologia Oncologia (ARGO 96) Study Group Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol. 2001;81:3–9
  43. See HT, Kavanagh JJ. Novel agents in epithelial ovarian cancer. Cancer Invest. 2004;22(suppl 2):29–44
  44. Cannistra SA, Matulonis U, Penson R, et al. Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J Clin Oncol. 2006;24:257s;(abstr 5006)
  45. Monk BJ, Han E, Josephs-Cowan CA, et al. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol. 2006;102:140–144
  46. Bidus MA, Webb JC, Seidman JD, et al. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol Oncol. 2006;102:5–7
  47. Wright JD, Alvarezsecord A, Numnum TM, et al. A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer. J Clin Oncol. 2006;24:260s;(abstr 5019)
  48. Cohn DE, Valmadre S, Resnick KE, et al. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol. 2006;102:134–139
  49. Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006;24:4324–4332
  50. Bookman MA, Darcy KM, Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:283–290
  51. Gordon AN, Finkler N, Edwards RP, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: Results from a phase II multicenter study. Int J Gynecol Cancer. 2005;15:785–792
  52. Schilder RJ, Sill MW, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: A Gynecologic Oncology Group Study. Clin Cancer Res. 2005;11:5539–5548
  53. Campos S, Hamid O, Seiden MV, et al. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol. 2005;23:5597–5604
  54. Wei SH, Brown R, Huang TH. Aberrant DNA methylation in ovarian cancer: Is there an epigenetic predisposition to drug response?. Ann N Y Acad Sci. 2003;983:243–250
  55. Strathdee G, MacKean MJ, Illand M, et al. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 1999;18:2335–2341
  56. Gifford G, Paul J, Vasey PA, et al. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res. 2004;10:4420–4426
  57. Bueno R, Appasani K, Mercer H, et al. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;121:225–233
  58. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992;52:3396–3401
  59. Garin-Chesa P, Campbell I, Saigo PE, et al. Trophoblast and ovarian cancer antigen LK26 (Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein). Am J Pathol. 1993;142:557–567
  60. Parker N, Turk MJ, Westrick E, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005;338:284–293
  61. Konner JA, Ahmed S, Gerst N, et al. Phase I study of MORAb-003, a humanized anti-folate receptor-alpha monoclonal antibody, in platinum resistant ovarian cancer. J Clin Oncol. 2006;24:262s;(abstr 5027)
  62. Gibbs DD, Theti DS, Wood N, et al. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res. 2005;65:11721–11728

PII: S0093-7754(07)00066-8

doi: 10.1053/j.seminoncol.2007.03.012

Seminars in Oncology
Volume 34 , Pages S1-S15 , April 2007

Article Tools

* Image Usage & Resolution